Neurocrine Biosciences (($NBIX)) announced an update on their ongoing clinical study. Neurocrine Biosciences has recently completed a Phase 2 ...

Key Takeaways Ketamine isn’t effective in treating depression, new clinical trial results indicateKetamine did not provide ...

Women are genetically at higher risk of clinical depression than men, Australian researchers found in a study published Wednesday that could change how the disorder is treated.

An important study published in JAMA Psychiatry (2025) challenges some of the most popular narratives about ketamine ’s ...

A new study announced Wednesday shows that psilocybin -- the active compound in "magic mushrooms" -- and mindfulness training ...

Okanagan Clinical Trials is inviting individuals living with major depressive disorder to participate in an ongoing ...

Psilocybin, the main psychoactive ingredient in magic mushrooms, could alleviate depression for at least five years after just one dose, according to a new study. The research, presented June 18 at ...

Psilocybin, the main psychoactive ingredient in magic mushrooms, could alleviate depression for at least five years after just one dose, according to a new study. The research, presented June 18 at ...

The termination of thousands of federal grants that fund clinical trials threatens to reverse substantial progress in ...